Xiaoyu Lv

Xiaoyu Lv

Auto-generated profile, based on publicly available information

Xiaoyu Lv

The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
XLXiaoyu Lv
Xiaoyu Lv
HWHui Wang
Hui Wang
CCChongyang Chen
Chongyang Chen
YZYangting Zhao
Yangting Zhao
KLKai Li
Kai Li
JLJingfang Liu
Jingfang Liu
To explore the effects of Tirzepatide (TZP), a new hypoglycemic drug, on weight, blood lipids and blood pressure in overweight/obese patients with type 2 diabetes mellitus (T2DM). Relevant studies investigating the influence of TZP therapy on weight, lipid profiles and blood pressure in overweight/obese T2DM patients were selected from the PubMed, Embase, Web of Science and Cochrane databases from establishment until November 2022. A systematic review and meta-analysis were conducted to evaluate the effect of TZP on weight, blood lipids and blood pressure in overweight/obese patients with T2DM. Eight randomized controlled trials (RCTs), comprising 7491 patients with T2DM, were included in the meta-analysis. Results showed that compared with the glucagon-like peptide-1 receptor agonist (GLP-1RA), insulin, and placebo groups, body weight, triglycerides (TG), very low-density lipoprotein cholesterol (VLDL-C), total cholesterol (TC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and glycosylated hemoglobin (HbA1c) levels were significantly decreased in the TZP-treated groups, while high-density lipoprotein cholesterol (HDL-C) levels increased. With the gradual increase of TZP doses, the proportions of T2DM patients with weight loss >5% gradually increased. The 10 mg and 15 mg TZP doses had a stronger effect on the levels of TG, VLDL-C, and HDL-C. Moreover, the reduction in SBP levels in the 15 mg TZP-treated group was more pronounced than those in the 10 mg and 5 mg TZP-treated groups [MD=−2.07, 95% CI (−2.52, −1.63) and MD=−3.14, 95% CI (−4.42, −1.87)]. Compared with GLP-1RA, insulin, and placebo groups, the proportions of patients with HbA1c<7% in 10mg and 15mg TZP-treated groups were significantly higher than in the 5mg TZP-treated group [OR=1.53, 95% CI (1.25, 1.8)], OR=1.7, 95% CI (1.15, 2.50)].There was no significant difference regarding the risk of adverse reactions.

25 March 2024 in Postgraduate Medicine
Verified
Journal Article
Closed access
CCChongyang Chen
Chongyang Chen
YZYangting Zhao
Yangting Zhao
XLXiaoyu Lv
Xiaoyu Lv
KLKai Li
Kai Li
YWYawen Wang
Yawen Wang
JLJingfang Liu
Jingfang Liu
Objective: To investigate the correlation between serum ferritin (SF) and bone turnover markers in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD). Methods: Seven hundred and forty-two people with T2DM were selected. Serum bone turnover markers: osteocalcin (OC), type I procollagen N-terminal peptide (PINP), beta-I type collagen carboxy-terminal peptide (beta-CTx), and 25-hydroxyvitamin D3 (25-[OH]-D) levels were detected. High SF (HF) was defined as the indicated SF levels above 400 ng/mL in males and more than 150 ng/mL in females. Patients were divided into four groups: T2DM+normal SF (non-HF); T2DM+high SF (HF); T2DM+NAFLD+non-HF; andT2DM+NAFLD+HF. Relationships between SF and bone turnover markers were analyzed. Results: Compared with the T2DM+non-HF group, beta-CTx levels were higher in the T2DM+HFgroup. Compared with the T2DM+NAFLD+non-HF group, beta-CTx levels were increased and 25-(OH)-D levels decreased in the T2DM+NAFLD+HF group (all p < 0.05). SF was positively correlated with beta-CTx [beta = 0.074; 95% CI (0.003, 0.205)] and negatively correlated with 25-(OH)-D [beta=-0.108; 95%CI (-0.006, -0.001)]. Compared with the T2DM+non-HF group, an independent positive correlation was found between beta-CTx and SF in the T2DM+NAFLD+HF group [OR = 1.002; 95% CI (1.001, 1.004)]. Among males, SF was positively correlatedwith beta-CTx [beta = 0.114; 95% CI (0.031, 0.266)]. SF was negatively correlated with 25-(OH)-D levels in both male and female patients [beta=-0.124; 95% CI (0.007,0.001) and beta=-0.168; 95% CI (-0.012, -0.002)]. Among those >50 years of age and postmenopausal females, SF was negatively correlated with 25-(OH)-D levels [beta=-0.117; 95% CI (-0.007, -0.001) and beta=-0.003; 95% CI (-0.013, -0.003)]. Conclusion: SF level was positively correlated with beta-CTx in T2DM patients with NAFLD, which may promote bone resorption and increase the risk of bone loss.

1 April 2025 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
DMDengrong Ma
Dengrong Ma
PZPingping Zhao
Pingping Zhao
JGJie Gao
Jie Gao
XGXinyuan Guo
Xinyuan Guo
MHMei Han
Mei Han
JLJingfang Liu
Jingfang Liu
Purpose: To investigate the association between impaired thyroid hormone sensitivity and diabetic nephropathy (DN) in euthyroid patients with type 2 diabetes mellitus (T2DM). Methods: 1305 euthyroid patients with T2DM who were hospitalized in the Endocrinology Department of the First Hospital of Lanzhou University between July 2021 and August 2023 were selected. Several indices, such as the parameters thyroid feedback quantile index (PTFQI), thyroid feedback quantile index (TFQI), thyroid stimulating hormone index (TSHI), serum-free triiodothyronine to free thyroxine (FT3/FT4) ratio, and thyrotropin thyroxine resistance index (TT4RI) to evaluate thyroid hormone sensitivity were used. The patients were subdivided into four groups (Q1 to Q4) based on the quartile levels of the five indices. The correlation between thyroid hormone sensitivity and DN was analyzed by binary logistic regression and restricted cubic spline (RCS) analysis. Results: The levels of PTFQI, TFQI, and TSHI in the DN group were higher than those in the Non-DN group [0.04(− 0.21, 0.31) vs − 0.003(− 0.27, 0.25), 0.05(− 0.20, 0.30) vs 0.006(− 0.26, 0.25), 2.54± 0.52 vs 2.47± 0.51, all P< 0.05], while the FT3/FT4 levels were decreased in the DN group (0.40± 0.07 vs 0.42± 0.07, P< 0.05). Multivariate logistic regression analysis showed that the increase in PTFQI and TFQI levels was positively correlated with DN [OR=1.518, 95% CI(1.074, 2.145) and OR=1.546, 95% CI(1.084, 2.204)]. RCS showed a linear dose-response relationship between PTFQI, TFQI, TSHI, FT3/FT4, TT4RI, and the tendency of DN (all Pnon-linear> 0.05). As the levels of PTFQI, TFQI, and TSHI increased, and the FT3/FT4 levels decreased, the prevalence of DN and the urinary albumin-to-creatinine (UACR) level showed an upward trend (all Ptrend test< 0.05), while the estimated glomerular filtration rate (eGFR) level showed a downward trend (all Ptrend test< 0.05). Conclusion: Among euthyroid patients with T2DM, impaired thyroid hormone sensitivity is associated with DN, as well as elevated UACR levels and decreased eGFR levels.

23 July 2024 in Postgraduate Medicine
Verified
Journal Article
Closed access
YZYangting Zhao
Yangting Zhao
KLKai Li
Kai Li
CCChongyang Chen
Chongyang Chen
XLXiaoyu Lv
Xiaoyu Lv
YWYawen Wang
Yawen Wang
JLJingfang Liu
Jingfang Liu
Nephrogenic diabetes insipidus (NDI) is a rare genetic disorder primarily associated with mutations in the arginine vasopressin receptor 2 (AVPR2) gene or the aquaporin 2 (AQP2) gene, resulting in impaired water reabsorption in the renal tubules. This report describes a case of a young male patient with NDI from China with a history of polydipsia and polyuria for over 15 years. Laboratory examinations of the proband indicated low urine-specific gravity and osmolality. Urologic ultrasound revealed severe bilateral hydronephrosis in both kidneys, bilateral dilatation of the ureters, roughness of the bladder wall, and the formation of muscle trabeculae. The diagnosis of diabetes insipidus was confirmed by water deprivation tests. The administration of posterior pituitary hormone did not alter urine-specific gravity, and osmolality remained at a low level (C) in exon 3 of the AVPR2 gene of the proband was found, caused by the substitution of amino acid valine to leucine at position 206 [p.Val206Leu], which was a hemizygous mutation and consistent with X-chromosome recessive inheritance. The administration of oral hydrochlorothiazide improves the symptoms of polydipsia and polyuria in the proband. This novel AVPR2 gene mutation may be the main cause of NDI in this family, which induces a functional defect in AVPR2, and leads to reduced tubular reabsorption of water.

3 April 2026 in Postgraduate Medicine
Verified
Journal Article
Closed access
BPBinjing Pan
Binjing Pan
XLXiaoyu Lv
Xiaoyu Lv
XGXinyuan Guo
Xinyuan Guo
JLJingfang Liu
Jingfang Liu
1. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease, defined as the accumulation of liver fat up to 5%, and it affects approximatel...

1 July 2026 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
CCChen Chongyang
Chen Chongyang
ZYZhao Yangting
Zhao Yangting
LKLi Kai
Li Kai
LXLv Xiaoyu
Lv Xiaoyu
WYWang Yawen
Wang Yawen
JLJingfang Liu
Jingfang Liu
Most cases associated with Hereditary Severe Insulin Resistance Syndrome (H-SIRS) are linked to mutations in the insulin receptor (INSR) gene. Patients with H-SIRS typically manifest symptoms of hyperinsulinemia, insulin resistance, and diabetes mellitus. Other symptoms include impaired glucose regulation, hyperandrogenism, and the presence of acanthosis nigricans (AN). In this report, we present two cases of H-SIRS in female children exhibiting various symptoms, such as hyperinsulinemia, fasting hypoglycemia, postprandial hyperglycemia, overweight, fatty liver, hyperandrogenism, and varying degrees of AN. One patient also presented with mental retardation. Gene sequencing identified specific mutations in the INSR gene for both patients: c.2663A > G (p.Tyr888Cys) and c.38_61del (p.Pro13_Ala20del). These mutations have the potential to disrupt the interaction between INSR and insulin, leading to abnormal insulin signaling, insulin resistance, and various clinical manifestations.